The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
Weight-loss medications like Ozempic have gained immense popularity, but questions about potential muscle loss persist. Experts explain the mechanisms behind fat and muscle changes during treatment, emphasizing the importance of diet and exercise to maintain strength. Key strategies include resistance training and adequate protein to mitigate risks.
GLP-1 medications, originally for diabetes and now used for weight loss, are influencing more than just health—they're altering how people eat, shop, and make choices. This shift has major implications for business leaders. Health tracking apps like Shotlee can help monitor these behavioral changes.
When individuals search for 'weight loss,' Ozempic often appears prominently despite lacking FDA approval for that purpose. This occurs through paid search advertisements that bypass traditional ad regulations. Experts urge consumers to seek independent sources for accurate health information.
An Instagram video by a personal trainer offering advice on how to get 'skinny' legs has drawn criticism. The video, which gained nearly 400,000 views, sparked debate within the fitness community, with some experts warning against the potentially harmful messaging.
A recent article highlights key considerations for individuals seeking qualified medical weight loss providers, particularly concerning GLP-1 treatments. It stresses the importance of thorough evaluations, ongoing monitoring, and comprehensive plans for effective and sustainable weight management.
Discover the leading semaglutide choices for weight loss in 2026. This article examines FDA-approved GLP-1 programs, safety protocols, access methods, and the structure of MEDVi's online weight loss platform. As medical weight loss evolves, understanding the best options is crucial.
This article explores the use of Ozempic for weight loss, examining its effectiveness and safety. It also provides information on PhenQ as an alternative weight loss supplement.
Investing in Novo Nordisk (NVO), the maker of Ozempic and Wegovy, has faced challenges recently, with shares declining. However, recent FDA approval of an oral form of Wegovy could change the company's trajectory. Analyzing competition and market dynamics is vital for investment decisions.
As weight loss becomes a popular New Year's resolution, many are turning to GLP-1 medications. However, scammers are leveraging fake websites and offers to steal money and personal data. The Better Business Bureau warns of fraudulent schemes targeting those seeking weight loss solutions.
